Intergroupe Francophone De Cancerologie Thoracique

This trial tested whether a shorter, 6-month course of immunotherapy is as effective as continuing treatment until the cancer worsens for patients with advanced lung cancer. It involved 265 patients who had already responded to initial immunotherapy. The goal was to see if stoppi…

This study tested the safety and effectiveness of the immunotherapy drug durvalumab in a group of patients often excluded from cancer trials: those with advanced lung cancer who were too frail for standard chemotherapy. It enrolled 50 treatment-naive patients with stage IV non-sm…